查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1362979

光化性角化症治疗市场规模、份额和趋势分析报告：2023-2030 年按治疗、药物类别、最终用途、地区和细分市场进行的预测

Actinic Keratosis Treatment Market Size, Share & Trends Analysis Report By Therapy (Topical, Surgery, Photodynamic Therapy), By Drug Class, By End-use, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 170 Pages | 商品交期: 2-10个工作天内

价格

光化性角化症治疗市场的成长与趋势：

根据Grand View Research, Inc.最新报告，预计到2030年，全球光化性角化病治疗市场规模将达到89亿美元，2023年至2030年年复合成长率为4.3%。

由于光化性角化病药物的广泛使用、对该疾病的认识不断提高以及 AK 治疗数量的增加等要素，预计该市场将出现成长机会。此外，全球光化性角化病患患病的增加和老年人口的增加预计将在预测期内推动市场成长。

AK 恶性化（iSCC）后可发展为恶性鳞状细胞癌。儘管 iSCC 有多种潜在原因，但 AK 是最常见的原因之一。此外，基底细胞癌和非黑色素瘤皮肤癌也可能由 AK 引起。因此，光化性角化症的早期诊断和治疗作为预防併发症的策略，推动了整个销售管道对 AK 产品的需求。

此外，越来越多的未来管道药物和联合治疗正在促进因素市场发展。例如，南澳 Almirall 的 Klisyri（扩大适应症）处于 III 期研究和开发阶段。此外，创新药物的接受度和商业化程度的提高是预计推动市场成长的另一个要素。此外，研发活动的活性化预计将加速用于治疗光化性角化症的新药的核准，从而推动预测期内的成长。

主要企业正在采取产品发布、联盟和扩大策略等策略倡议，以增加市场占有率。例如，2022 年 6 月，BIOFRONTERA AG 宣布，总部位于瑞士的 Louis Widmer SA 已获得 Ameluz 治疗身体躯干、四肢和颈部光化性角化病的营销核准延期。此外，BIOFRONTERA AG 于 2020 年 7 月宣布，已与 Galenica AB 签署协议，在挪威、芬兰、挪威和冰岛分销 BF-RhodoLED 和 Ameluz。

光化性角化症治疗市场报告亮点

  • 2022 年，由于越来越多地采用冷冻疗法治疗光化性角化病，外科手术占据了最大的销售份额，达到 65.6%。
  • 核苷代谢抑制剂在2022年占据最大的收益占有率，为32.4%，预计在预测期内将保持其主导地位。
  • 由于 AK患病、医疗基础设施快速发展以及亚太国家医疗保健支出增加等要素，预计亚太地区在预测期内将以 5.6%的年复合成长率增长最快。
  • 由于公众对光化性角化病的认识提高、有效治疗方案的可用性以及医疗基础设施的改善，北美在 2022 年以 41.5% 的最大销售份额占据市场主导地位。

目录

第1章调查方法和范围

第2章执行摘要

第3章光化性角化症治疗市场变数、趋势与范围

  • 市场体系预测
    • 母市场预测
    • 相关/附随市场预测
  • 普及和成长预测图
  • 市场动态
    • 市场促进因素分析
    • 市场抑制因素分析
  • 光化性角化症治疗市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第4章光化性角化症治疗市场：治疗估计与趋势分析

  • 光化性角化症治疗市场：重点
  • 光化性角化症治疗市场：2022 年和 2030 年趋势和市场占有率分析
  • 局部的
  • 外科手术
  • 光动力疗法

第5章光化性角化症治疗市场：药物类别估计与趋势分析

  • 光化性角化症治疗市场：重点
  • 光化性角化症治疗市场：2022 年和 2030 年趋势和市场占有率分析
  • 核苷代谢抑制剂
  • NSAIDS
  • 免疫反应调节剂
  • 照片增强剂
  • 其他的

第6章光化性角化症治疗市场：最终用途估计与趋势分析

  • 光化性角化症治疗市场：重点
  • 光化性角化症治疗市场：2022 年和 2030 年趋势和市场占有率分析
  • 医院
  • 私人诊所
  • 居家护理
  • 其他的

第7章光化性角化症治疗市场：区域估计与趋势分析

  • 区域展望
  • 光化性角化症治疗市场（按地区）：要点
  • 北美洲
    • 2018-2030 年市场估计与预测
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿拉伯聯合大公国
    • 科威特

第8章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 市场参与企业分类
    • Almirall SA
    • LEO Pharma A/S
    • Sun Pharmaceutical Industries Ltd.
    • Novartis AG
    • GALDERMA
    • Ortho Dermatologics (Bausch Health Companies Inc.)
    • BIOFRONTERA AG
    • Hill Dermaceuticals, Inc.
Product Code: GVR-2-68038-940-1

Actinic Keratosis Treatment Market Growth & Trends:

The global actinic keratosis treatment market size is expected to reach USD 8.9 billion by 2030, registering a CAGR of 4.3% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The market is expected to witness growth opportunities owing to factors such as the wide availability of actinic keratosis therapeutics, rising awareness about the disease, and the rise in AK treatment. Moreover, the increasing prevalence of actinic keratosis and the rising geriatric population across the globe are expected to fuel the market growth during the forecast period.

Invasive squamous cell carcinoma may develop from AK when it becomes malignant (iSCC). Despite the fact that there are a number of potential causes for iSCC, AK is one of the most frequent ones. Additionally, basal cell carcinoma and non-melanoma skin cancer could result from AK. As a result, the demand for AK products across sales channels is being driven by the early diagnosis and treatment of actinic keratosis as a preventive strategy for comorbidities.

In addition, future pipeline medications and the increased use of combination therapy are key market drivers. For instance, Almirall, S.A. has Klisyri (extended label) in phase III of R&D. Furthermore, a rise in the acceptance and commercialization of innovative drugs is another factor that is predicted to fuel market growth. Moreover, increased R&D activities are expected to accelerate the approval of novel drugs used in the treatment of actinic keratosis, hence, propelling the growth over the forecast period.

Key players are adopting strategic initiatives such as product launches, partnerships, and expansion strategies to increase their market share across the globe. For instance, in June 2022, BIOFRONTERA AG announced that its license and marketing authorization holder Louis Widmer SA based in Switzerland has received an extension of its marketing authorization for the management of actinic keratosis in the trunk, extremities, and neck with Ameluz. Moreover, in July 2020, BIOFRONTERA AG announced that it has signed an agreement with Galenica AB for the marketing of BF-RhodoLED and Ameluz in Norway, Finland, Norway, and Iceland.

Actinic Keratosis Treatment Market Report Highlights:

  • Surgery held the largest revenue share of 65.6% in 2022 owing to the rising adoption of cryotherapy surgery in the management of actinic keratosis
  • Nucleoside metabolic inhibitors held the largest revenue share of 32.4% in 2022 and is expected to retain its dominance over the forecast period
  • Asia Pacific is expected to grow at the fastest CAGR of 5.6% during the forecast period due to factors such as the high prevalence of AK, rapidly evolving healthcare infrastructure, and rising healthcare expenditures by Asia Pacific countries
  • North America dominated the market with the largest revenue share of 41.5% in 2022 due to the rising awareness among people about actinic keratosis, availability of robust treatment options, and improvements in healthcare infrastructure

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Therapy
    • 1.1.2. Drug class
    • 1.1.3. End-use
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Therapy outlook
    • 2.2.2. Drug class outlook
    • 2.2.3. End-use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Actinic Keratosis Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Actinic Keratosis Treatment Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Actinic Keratosis Treatment Market: Therapy Estimates & Trend Analysis

  • 4.1. Actinic Keratosis Treatment Market: Key Takeaways
  • 4.2. Actinic Keratosis Treatment Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Topical
    • 4.3.1. Topical market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Surgery
    • 4.4.1. Surgery market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Photodynamic Therapy
    • 4.5.1. Photodynamic therapy market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Actinic Keratosis Treatment Market: Drug Class Estimates & Trend Analysis

  • 5.1. Actinic Keratosis Treatment Market: Key Takeaways
  • 5.2. Actinic Keratosis Treatment Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Nucleoside Metabolic Inhibitor
    • 5.3.1. Nucleoside metabolic inhibitor market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. NSAIDS
    • 5.4.1. NSAIDS market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Immune Response Modifiers
    • 5.5.1. Immune response modifiers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Photoenhancers
    • 5.6.1. Photoenhancers market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Actinic Keratosis Treatment Market: End-use Estimates & Trend Analysis

  • 6.1. Actinic Keratosis Treatment Market: Key Takeaways
  • 6.2. Actinic Keratosis Treatment Market: Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Hospitals
    • 6.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4. Private Clinics Delivery
    • 6.4.1. Private clinics delivery market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Homecare
    • 6.5.1. Homecare market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Actinic Keratosis Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Outlook
  • 7.2. Actinic Keratosis Treatment Market by Region: Key Takeaway
  • 7.3. North America
    • 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.3. France
      • 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.6. Sweden
      • 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.7. Norway
      • 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.2. China
      • 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.3. India
      • 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.5. Thailand
      • 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.2. Mexico
      • 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7. MEA
    • 7.7.1. Saudi Arabia
      • 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Market Participant Categorization
    • 8.2.1. Almirall S.A.
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. LEO Pharma A/S
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Sun Pharmaceutical Industries Ltd.
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Novartis AG
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. GALDERMA
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Ortho Dermatologics (Bausch Health Companies Inc.)
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. BIOFRONTERA AG
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Hill Dermaceuticals, Inc.
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives 

List of Tables

  • 1. List of Abbreviations
  • 2. North America actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 3. North America actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 4. North America actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 5. North America actinic keratosis treatment market, by region, 2018 - 2030 (USD Million)
  • 6. U.S. actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 7. U.S. actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 8. U.S. actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 9. Canada actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 10. Canada actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 11. Canada actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 12. Europe actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 13. Europe actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 14. Europe actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 15. Europe actinic keratosis treatment market, by region, 2018 - 2030 (USD Million)
  • 16. Germany actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 17. Germany actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 18. Germany actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 19. UK actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 20. UK actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 21. UK actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 22. France actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 23. France actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 24. France actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 25. Italy actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 26. Italy actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 27. Italy actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 28. Spain actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 29. Spain actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 30. Spain actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 31. Sweden actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 32. Sweden actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 33. Sweden actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 34. Norway actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 35. Norway actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 36. Norway actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 37. Denmark actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 38. Denmark actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 39. Denmark actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 40. Asia Pacific actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 41. Asia Pacific actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 42. Asia Pacific actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 43. Asia Pacific actinic keratosis treatment market, by region, 2018 - 2030 (USD Million)
  • 44. China actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 45. China actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 46. China actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 47. Japan actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 48. Japan actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 49. Japan actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 50. India actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 51. India actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 52. India actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 53. Thailand actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 54. Thailand actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 55. Thailand actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 56. South Korea actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 57. South Korea actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 58. South Korea actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 59. Latin America actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 60. Latin America actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 61. Latin America actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 62. Latin America actinic keratosis treatment market, by region, 2018 - 2030 (USD Million)
  • 63. Brazil actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 64. Brazil actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 65. Brazil actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 66. Mexico actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 67. Mexico actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 68. Mexico actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 69. Argentina actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 70. Argentina actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 71. Argentina actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 72. Middle East and Africa actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 73. Middle East and Africa actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 74. Middle East and Africa actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 75. Middle East and Africa actinic keratosis treatment market, by region, 2018 - 2030 (USD Million)
  • 76. South Africa actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 77. South Africa actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 78. South Africa actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 79. Saudi Arabia actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 80. Saudi Arabia actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 81. Saudi Arabia actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 82. UAE actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 83. UAE actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 84. UAE actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)
  • 85. Kuwait actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • 86. Kuwait actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • 87. Kuwait actinic keratosis treatment market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • 1. Market research process
  • 2. Data triangulation techniques
  • 3. Primary research pattern
  • 4. Market research approaches
  • 5. Value-chain-based sizing & forecasting
  • 6. QFD modeling for market share assessment
  • 7. Market formulation & validation
  • 8. Actinic keratosis treatment: Market outlook
  • 9. Actinic keratosis treatment: Competitive insights
  • 10. Parent market outlook
  • 11. Related/ancillary market outlook
  • 12. Penetration and growth prospect mapping
  • 13. Industry value chain analysis
  • 14. Actinic keratosis treatment market driver impact
  • 15. Actinic keratosis treatment market restraint impact
  • 16. Actinic keratosis treatment market strategic initiatives analysis
  • 17. Actinic keratosis treatment market: Therapy movement analysis
  • 18. Actinic keratosis treatment market: Therapy outlook and key takeaways
  • 19. Topical market estimates and forecasts, 2018 - 2030 (USD Million)
  • 20. Surgery market estimates and forecasts, 2018 - 2030 (USD Million)
  • 21. Photodynamic therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • 22. Actinic keratosis treatment market: Drug class movement analysis
  • 23. Actinic keratosis treatment market: Drug class outlook and key takeaways
  • 24. Nucleoside metabolic inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • 25. NSAIDS market estimates and forecasts, 2018 - 2030 (USD Million)
  • 26. Immune response modifiers market estimates and forecasts, 2018 - 2030 (USD Million)
  • 27. Photoenhancers market estimates and forecasts, 2018 - 2030 (USD Million)
  • 28. Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • 29. Actinic keratosis treatment market: End-use movement analysis
  • 30. Actinic keratosis treatment market: End-use outlook and key takeaways
  • 31. Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
  • 32. Private clinics delivery market estimates and forecasts, 2018 - 2030 (USD Million)
  • 33. Homecare market estimates and forecasts, 2018 - 2030 (USD Million)
  • 34. Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • 35. Global actinic keratosis treatment market: Regional movement analysis
  • 36. Global actinic keratosis treatment market: Regional outlook and key takeaways
  • 37. North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • 38. U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • 39. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • 40. Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • 41. UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • 42. Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • 43. France market estimates and forecasts, 2018 - 2030 (USD Million)
  • 44. Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • 45. Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • 46. Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • 47. Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • 48. Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • 49. Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • 50. Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • 51. China market estimates and forecasts, 2018 - 2030 (USD Million)
  • 52. India market estimates and forecasts, 2018 - 2030 (USD Million)
  • 53. Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • 54. Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • 55. South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • 56. Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • 57. Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • 58. Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • 59. Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • 60. Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • 61. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • 62. South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • 63. UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • 64. Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)